All In Biotech

Drug Trial Radar · NCT07518459

A Study of Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]AZD4144

An Open-Label, Two-Cohort Study of Absorption, Distribution, Metabolism, Excretion (ADME) of [14C]AZD4144 Following a Single Oral and IV Dose to Healthy Male Participants

Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Feb 11, 2026

Primary completion

May 26, 2026

Study completion May 26, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Quotient Sciences
First posted
Apr 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 30 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study in healthy volunteers aims to explore blood levels and side effects of the test medicine, and look at how it is broken down when injected into a vein or given as a liquid by mouth. The test medicine will be radiolabeled with a small amount of carbon-14 so it can be tracked in the body. This study will take place at one site in Nottingham, United Kingdom, and will enroll 2 groups of 8 healthy men aged 30-65 years.

Conditions

  • Healthy Participants

Interventions

  • [14C]AZD4144 Solution for InfusionDrug

    Intravenous, fasted

  • [14C]AZD4144 Oral SolutionDrug

    Oral, fasted

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Amount of AZD4144 excreted (Ae)Time frame: Urine and faecal samples collected from pre-dose until up to 216 hours post-dose
  2. Amount of AZD4144 excreted expressed as a percentage of the radioactive dose administered (Fe)Time frame: Urine and faecal samples collected from pre-dose until up to 216 hours post-dose
  3. Cumulative amount of AZD4144 excreted (CumAe)Time frame: Urine and faecal samples collected from pre-dose until up to 216 hours post-dose
  4. Cumulative amount of AZD4144 excreted expressed as a percentage of the radioactive dose administered (CumFe)Time frame: Urine and faecal samples collected from pre-dose until up to 216 hours post-dose
  5. Area under the curve (AUC) of circulating plasma total radioactivity (TR) accounting for 10% or more of the doseTime frame: Plasma, urine and faecal samples from pre-dose until up to 216 hours post-dose
  6. 80% or more of the radioactivity recovered in excretaTime frame: Plasma, urine and faecal samples from pre-dose until up to 216 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Ruddington, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.